CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed refractory solid tumor and/or lymphoma
• No brain metastases or primary CNS malignancies
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• More than 3 months
• Hematopoietic:
• Granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin normal
• ALT and AST less than 2.5 times normal
• Renal:
• Creatinine no greater than 1.5 mg/dL OR
• Creatinine clearance greater than 60 mL/min
• Cardiovascular:
• No unstable or newly diagnosed angina pectoris
• No myocardial infarction within the past 6 months
• No New York Heart Association class II, III, or IV congestive heart failure
• Pulmonary:
• No chronic obstructive lung disease requiring oxygen therapy
• Other:
• No uncontrolled seizures
• No concurrent acute critical illness
• No serious untreated infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior biologic therapy
• Chemotherapy:
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or carboplatin)
• No concurrent cytotoxic chemotherapy
• Endocrine therapy:
• At least 4 weeks since prior hormonal therapy
• Concurrent luteinizing hormone-releasing hormone agonist required in patients with prostate cancer unless prior orchiectomy has been performed
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• Surgery:
• See Endocrine therapy
• Prior surgery allowed
• Other:
• Recovered from prior therapy
• No concurrent anticonvulsants (e.g., phenobarbital, phenytoin, or carbamazepine)
• No concurrent rifampin
• No concurrent grapefruit juice